Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Corporation, often referred to as MTPC, is a prominent player in the global pharmaceutical industry, headquartered in Japan. Established in 1678, the company has evolved significantly, focusing on innovative drug development and therapeutic solutions primarily in the fields of neurology, immunology, and diabetes care. With a strong presence in Japan, North America, and Europe, Mitsubishi Tanabe Pharma is renowned for its unique core products, including treatments for multiple sclerosis and other chronic conditions. The company has achieved notable milestones, such as the successful launch of its flagship drug, which has positioned it as a leader in the biopharmaceutical market. Committed to advancing healthcare, Mitsubishi Tanabe Pharma continues to make significant contributions to patient well-being through its research and development initiatives.
DitchCarbon Score
How does Mitsubishi Tanabe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mitsubishi Tanabe Pharma's score of 43 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mitsubishi Tanabe Pharma's reported carbon emissions
Mitsubishi Tanabe Pharma, headquartered in Japan, has made significant strides in addressing its carbon emissions. In 2023, the company reported total emissions of approximately 700,900,000 kg CO2e, with Scope 1 emissions at about 18,700,000 kg CO2e and Scope 2 emissions at around 36,300,000 kg CO2e. The Scope 3 emissions, which encompass indirect emissions from the value chain, also accounted for a substantial portion of their total emissions. The company has set ambitious climate commitments, aiming for a 45% reduction in greenhouse gas (GHG) emissions by 2030 compared to fiscal 2019 levels. Furthermore, Mitsubishi Tanabe Pharma has established a long-term goal to achieve net-zero emissions by 2050, covering all domestic and overseas group companies. This commitment includes both Scope 1 and Scope 2 emissions, reflecting a comprehensive approach to sustainability. Overall, Mitsubishi Tanabe Pharma's proactive stance on climate action demonstrates its dedication to reducing its environmental impact and contributing to global efforts against climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 35,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 71,800,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mitsubishi Tanabe Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
